SUMMARY
Background Pending for randomized control trials, the use of tocilizumab (TCZ) in COVID-19 is based on observational studies and remains controversial.
Purpose To summarize evidence about the effect of TCZ to treat severe COVID-19.
Data sources PubMed (via MEDLINE), Scopus, and medRxiv repository databases from 1 January to 21 August 2020.
Study Selection Observational studies in any language reporting efficacy and safety outcomes of TCZ use in hospitalized adults with COVID-19.
Data Extraction Independent, dually performed data extraction and quality assessments.
Data synthesis Of 57 eligible studies, 27 were controlled and 30 were not. The overall included patients were 8,128: 4,021 treated with TCZ, in addition to standard of care (SOC), and 4,107 only receiving SOC. The pooled mortality was lower in the TCZ-group vs. the control group, with a relative risk (RR) of 0.73 (95%CI 0.57–0.93; p = 0.010). The overall NNT to avoid one death was 20. In hospital wards, patients in the TCZ-group were transferred to intensive care unit (ICU) in a higher proportion than those in the control group; however, ICU mortality of the TCZ-group was lower than in the control group. Secondary infections occurred in a higher proportion in TCZ-treated patients. Among survivors, the length of stay was similar in both groups.
Limitations Conclusions should be considered as weak evidence since they are based on observational studies, most of them retrospective. A variety of factors influencing the indication and effect of TCZ could not be evaluated in-depth.
Conclusions TCZ to seem beneficial in preventing in-hospital mortality in severe, non-critically ill COVID-19 patients. Conversely, patients receiving TCZ appear to be at higher risk for secondary infections, especially those admitted to ICU.
Funding source No funding or sponsorship was received for this study or publication of this article.
The protocol was published in the National Institute for Health Research international register of systematic reviews (PROSPERO); registration number CRD42020204934.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding or sponsorship was received for this study or publication of this article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received the ethics excemption by the Research Ethics Committee of Bellvitge University Hospital
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses: mrubio{at}bellvitgehospital.cat (M. Rubio-Rivas), jmora{at}bellvitgehospital.cat (J.M. Mora-Luján), asaez{at}bellvitgehospital.cat (A. Montero), nhoms{at}bellvitgehospital.cat (N.A. Homs), jrello{at}crips.es (J. Rello), xcorbella{at}bellvitgehospital.cat (X. Corbella)
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
